NMT Medical, AGA Medical settle
This article was originally published in The Gray Sheet
Executive Summary
In return for full and final settlement of NMT's 1999 patent infringement suit, AGA will pay NMT $30 mil. for a nonexclusive sublicense to patent '420, which relates to NMT's CardioSeal, the two firms announced March 28. The alleged infringement affects all AGA Amplatzer occluding devices. NMT will split the settlement with inventor Lloyd Marks, MD, according to the firm. NMT competes with AGA in the patent foramen ovale occlusion market with STARFlex. Preliminary results of NMT's MIST I trial suggest a connection between patent foramen ovale closure and migraine symptoms (1"The Gray Sheet" March 20, 2006, p. 3)...
You may also be interested in...
MIST Trial Reveals Mixed Results For PFO Treatment Of Migraine
Preliminary clinical trial data show NMT Medical's STARflex patent foramen ovale (PFO) closure device to be no more effective than placebo in completely eliminating migraine headaches, although the device did appear to improve some symptoms
NAC’s Longevity In US Dietary Supplement Market Swings On Comments As NDI Notifications
FDA ODSP details “data, research results, and other information” it needs on NAC that could sway proposing a rulemaking to allow its continued use in supplements. One detail missing is what the agency’s asking for are NDI notifications for NAC.
US FDA Communication Ahead Of Major Actions Could Counter Misinformation, Ex-Official Says
Instead of waiting until after regulatory events like COVID boosters and Aduhelm, FDA should describe its decision-making process along the way to help restore public faith in the agency, former deputy commissioner Josh Sharfstein says.